Clinical trials: Non-Small Cell Lung Cancer (NSCLC), open to volunteers
Non-Small Cell Lung Cancer (NSCLC)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum…
- Trial name
- NCT05920356
- Testing
- Sotorasib, Pembrolizumab
- Where
- 424 sites in United States, Argentina and 36 more
- Volunteers
- 750 people
- Sponsor
- Amgen
Carcinoma, Non-Small-Cell Lung (NSCLC)
Primary Radiotherapy In MEtastatic Lung Cancer
Lung cancer has the highest mortality rate of all cancers in Australia and is an area of unmet need. It starts in the lung (the primary tumour), and then spreads (metastasise) to other organs.
- Trial name
- PRIME-Lung (NCT07135882)
- Testing
- Radiotherapy followed by chemotherapy, Standard of Care (SOC)
- Where
- 6 sites in Australia
- Volunteers
- 420 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty.
- Trial name
- NCT07140016
- Testing
- gilteritinib
- Where
- 17 sites in United States, France and 1 more
- Volunteers
- 40 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic NSCLC - Non-Small Cell Lung Cancer
Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
This study investigates whether adding magnesium to the standard chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC) can improve treatment outcomes.
- Trial name
- NCT07149649
- Testing
- Magnesiocard, Magnesium Diasporal, Microcrystalline cellulose
- Where
- 11 sites in Switzerland
- Volunteers
- 230 people
- Sponsor
- Swiss Cancer Institute
Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
- Trial name
- NCT07361510
- Testing
- Pumitamig, Pembrolizumab
- Where
- 283 sites in United States, Argentina and 34 more
- Volunteers
- 750 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer (NSCLC)
Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer
In low-risk patients with stage I non-small cell lung cancer (NSCLC) surgical treatment with an anatomical resection is currently the standard of care.
- Trial name
- STRADOS (NCT07432802)
- Testing
- Stereotactic radiation therapy intervention, Surgical intervention
- Where
- 4 sites in Denmark
- Volunteers
- 182 people
- Sponsor
- Aarhus University Hospital
Lung Cancer (NSCLC), KRAS G12C Lung Cancer
Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)
This study is a multicenter, prospective, open-label clinical trial. It enrolls previously untreated patients with resectable stage IB-IIIB KRAS G12C mutation-positive NSCLC to evaluate the efficacy and safety of glesorasib…
- Trial name
- GIVEN (NCT07472478)
- Testing
- Garsorasib, Ivonescimab Combined With Chemotherapy, Surgery
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Guangdong Provincial People's Hospital
Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants…
- Trial name
- NCT07680764
- Testing
- Pumitamig, Imzokitug, Pemetrexed
- Where
- 74 sites in United States, Argentina and 10 more
- Volunteers
- 160 people
- Sponsor
- Bristol-Myers Squibb
Leptomeningeal Metastasis, Breast Cancer
BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor Malignancies
The purpose of this study is to determine the efficacy of BRain-AVOidant proton craniospinal irradiation (BRAVO pCSI) in adult participants with leptomeningeal metastases from solid tumors.
- Conditions
- Leptomeningeal Metastasis, Breast Cancer, Lung Cancer (NSCLC)
- Trial name
- BRAVO-LM (NCT07789912)
- Testing
- Radiation Treatments Using Brain- Avoidant Proton Craniospinal Irradiation (BRAVO- pCSI)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Miami
Mesothelioma, Pancreatic Cancer
A 2-part Phase 1/2 Open-label Trial on ODM-212
An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
- Conditions
- Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
- Trial name
- TEADCO (NCT07563738)
- Testing
- ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel
- Where
- 23 sites in United States, Denmark and 5 more
- Volunteers
- 229 people
- Sponsor
- Orion Corporation, Orion Pharma
Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC)
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors…
- Conditions
- Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer
- Trial name
- Luca-1 (NCT07705334)
- Testing
- SHY-ONC6
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- SHY Therapeutics
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity…
- Conditions
- NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage
- Trial name
- BActinium-2 (NCT07887971)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Aktis Oncology, Inc.
Cachexia; Cancer, Cachexia
OLE Study Subsequent to Parent Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
The purpose of the OLE study is to evaluate the long-term safety and tolerability of rilogrotug treatment in participants who have completed the parent study and are eligible to receive continued treatment.
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Trial name
- REACH-OLE (NCT07888075)
- Testing
- Rilogrotug
- Volunteers
- 400 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Liposarcoma, Prostate Cancer
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy.
- Conditions
- Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- CDK4i (NCT04557449)
- Testing
- PF-07220060, Letrozole, Fulvestrant
- Where
- 39 sites in United States, Argentina and 6 more
- Volunteers
- 430 people
- Sponsor
- Pfizer
Lung Cancer (NSCLC)
Postoperative Pulmonary Function Assessment Based on Deep Learning Study
Improvements in low-dose CT screening have led to an increase in early-stage NSCLC diagnoses, with surgical resection-usually lobectomy or segmentectomy-remaining the primary curative option.
- Trial name
- NCT07256457
- Testing
- Segmentectomy, Lobectomy, Bronchoscopic Ablation
- Where
- Hong Kong
- Volunteers
- 192 people
- Sponsor
- Chinese University of Hong Kong
Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
The treatment decisions, assessment schedule, and study procedures in this research will adhere to the routine clinical practice of each participating center.
- Conditions
- Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative, Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2, No Prior Systemic Therapy Received for the Advanced or Metastatic Disease
- Trial name
- PROMISE (NCT07696832)
- Testing
- Ivonescimab Injection
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Guangdong Association of Clinical Trials
Lung Cancer (NSCLC)
Navigation Bronchoscopy Guided Microwave Ablation Versus SBRT in Early NSCLC
Background: Stereotactic body radiotherapy (SBRT) is a standard definitive local therapy for medically inoperable early stage non-small cell lung cancer (NSCLC).
- Trial name
- NCT07722182
- Testing
- Navigation Bronchoscopy-Guided Microwave Ablation, Stereotactic Body Radiotherapy (SBRT)
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- Chinese University of Hong Kong
Stage IA NSCLC
Study of Robotic Assisted/Image Guided Electromagnetic Navigation Bronchoscopic Therapies and Surgery in Stage IA NSCLC
This study aims to address the core deficiencies in the field by situating bronchoscopic ablation within the same evidentiary frame as segmentectomy and lobectomy.
- Trial name
- NCT07741344
- Testing
- Bronchoscopic Microwave Ablation, Surgical Resection
- Where
- Hong Kong
- Volunteers
- 292 people
- Sponsor
- Chinese University of Hong Kong
Non-Small Cell Lung Cancer (NSCLC)
MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
Neoadjuvant immunotherapy combined with platinum-based doublet chemotherapy has been established as the standard of care for driver-gene-negative (EGFR/ALK wild-type) stage II-IIIB non-small cell lung cancer (NSCLC), yielding…
- Trial name
- NCT07885709
- Testing
- PD-1 inhibitor, Carboplatin, Nab-paclitaxel
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the…
- Conditions
- Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma
- Trial name
- NCT02133196
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)